Match!
Annals of the Rheumatic Diseases
IF
14.30
Papers
47980
Papers 47913
1 page of 4,792 pages (47.9k results)
Newest
#1Gabriele ValentiniH-Index: 48
#2Dörte Huscher (Charité)H-Index: 22
Last.Ulf Mueller-Ladner (University of Giessen)H-Index: 10
view all 36 authors...
Objectives To investigate the influence of vasodilator drugs on the occurrence of features depending on myocardial ischaemia/fibrosis (ventricular arrhythmias, Q waves, cardiac blocks, pacemaker implantation, left ventricular ejection fraction (LVEF) Methods 601 patients with SSc were enrolled from 1 December 2012 to 30 November 2015 and had a second visit 0.5–4 years apart. 153 received no vasodilators; 448 received vasodilator therapy (ie, calcium channel blockers and/or ACE inhibitors or angi...
2 CitationsSource
Therapeutic management of many cancers has been revolutionised by the development of immune checkpoint inhibitors (ICI) targeting antiprogrammed death 1 (PD-1)/ligand 1 (PDL1) and anticytotoxic T-lymphocyte antigen 4 leading to durable responses.1 ICIs however can induce several immune-related adverse events (irAE) including musculoskeletal irAEs.2 Among them, ICI-related myositis can be severe and sometimes life threatening.3 4 The current management includes permanent discontinuation of ICIs a...
Source
#1Ronghan Liu (NYU: New York University)H-Index: 2
#2Yuehong Chen (NYU: New York University)H-Index: 2
Last.Chuan-ju LiuH-Index: 39
view all 15 authors...
Objective Tumour necrosis factor alpha (TNF-α) signalling plays a central role in the pathogenesis of various autoimmune diseases, particularly inflammatory arthritis. This study aimed to repurpose clinically approved drugs as potential inhibitors of TNF-α signalling in treatment of inflammatory arthritis. Methods In vitro and in vivo screening of an Food and Drug Administration (FDA)-approved drug library; in vitro and in vivo assays for examining the blockade of TNF actions by fexofenadine: as...
1 CitationsSource
#1David Bursill (University of Adelaide)H-Index: 2
#2William J. TaylorH-Index: 45
Last.Nicola Dalbeth (University of Auckland)H-Index: 45
view all 79 authors...
Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participa...
1 CitationsSource
#1David A. Isenberg (UCL: University College London)H-Index: 103
I read with great interest the paper by Eric Morand and colleagues1 reporting on the utility of the Lupus Low Disease Activity State attainment using a useful form of discrimination in the phase IIb MUSE …
2 CitationsSource
#1Walter P. Maksymowych (U of A: University of Alberta)H-Index: 65
#2Robert G. W. Lambert (U of A: University of Alberta)H-Index: 38
Last.Xenofon Baraliakos (RUB: Ruhr University Bochum)H-Index: 41
view all 26 authors...
Objectives The Assessment of SpondyloArthritis international Society (ASAS) MRI working group (WG) was convened to generate a consensus update on standardised definitions for MRI lesions in the sacroiliac joint (SIJ) of patients with spondyloarthritis (SpA), and to conduct preliminary validation. Methods The literature pertaining to these MRI lesion definitions was discussed at three meetings of the group. 25 investigators (20 rheumatologists, 5 radiologists) determined which definitions should ...
1 CitationsSource
#1Manouk de HoogeH-Index: 10
#2Floris A. van Gaalen (LUMC: Leiden University Medical Center)H-Index: 16
Last.Filip Van den BoschH-Index: 35
view all 11 authors...
Inflammatory back pain (IBP) is considered so essential in the axial spondyloarthritis (axSpA) diagnostic process that it is recommended as referral parameter in primary care.1–3 However, axSpA patients without IBP do exist as well as patients with IBP that do not have an axSpA diagnosis, leaving IBP to be a strong and useful feature for recognising axSpA but not pathognomonic.4 5 A recent study in German chronic back pain patients with a suspicion of axSpA report on the performance of, among ot...
Source
We read with interest the new data from Lescoat et al and their interesting comments concerning our research letter on the identification of circulating cells coexpressing M1 and M2 phenotype markers in patients affected by systemic sclerosis (SSc) compared with healthy subjects (HSs).1 2 In their study, Lescoat et al evaluated the mean of fluorescence intensity of specific markers of M1 and M2 phenotypes (CD80, CD206, CD204, CD163, CD169 and CD200R1) in macrophage colony-stimulating factor (M-C...
1 CitationsSource
#2Varun DhirH-Index: 10
Last.Sanjay JainH-Index: 27
view all 5 authors...
We read with great interest the simplified predictive score ‘SPAR model’ by Wu et al .1 A simplified predictive score which can predict ‘fast progressors’ can be used to target and selectively recruit such patients for drug trials and finally lead to improvement in outcomes in the future. However, certain aspects require clarification. First, the external validity of the patients recruited is unclear. Although early interstitial lung disease (ILD) as defined in the study (<20% CT involvement) wo...
1 CitationsSource
#1Javier NarváezH-Index: 31
#2J. LLuchH-Index: 1
Last.Ivan CastellvíH-Index: 14
view all 6 authors...
We read with great interest the results of the double-blind phase 2 faSScinate clinical trial,1 in which there was encouraging (although not statistically significant) numerical improvement in skin thickening and evidence of less decline in lung function in patients with systemic sclerosis (SSc) treated with tocilizumab (TCZ) compared with those receiving placebo. Initial investigations with TCZ in patients with SSc demonstrated improvements in skin sclerosis and polyarthritis.2 3 Scleroderma-as...
1 CitationsSource
12345678910
Top fields of study
Physical therapy
Immunology
Rheumatoid arthritis
Diabetes mellitus
Medicine